Abstract
In the article shows that the itching that is associated with chronic liver diseases has a significant impact on the quality of life of patients. The main mechanisms responsible for itching, mostly still unclear. In the treatment of pruritus in patients with liver diseases with cholestasis first-line drugs are cholestyramine and ursodeoxycholic acid. In their ineffectiveness or the adverse effects development, rifampicin or phenobarbital can be used, with significant pruritus – opioid antahonists . The selective serotonin inhibitor sertaline can be administered as forth-line therapy. Recent advances in understanding the pathogenesis of pruritus lead to new avenues for the development of more effective treatment strategies. Along with pathogenetic therapy certainly the important role plays the treatment of the disease wich caused cholestasis. When failure pharmacotherapy can be used alternative therapies, including liver transplantation.
References
2. American Heart Association. Methodology Manual. http://www.heart.org/presenter.jhtml?identifier_3039683. Accessed February 2009.
3. Barnes L.B. The central nervous system activity profile of cholestatic pruritus / L.B. Barnes, M.D. Devous, T.S. Harris et al. // J. Hepatology. – 2009. – Vol. 50. – P. 375.
4. Chapman R. et al Diagnosis and management of primary sclerosing cholangitis / R. Chapman et al. // J.Hepatol. – 2010. – Vol. 51(2) – P. 661-678.
5. Europian Association for the Study of Liver // J.Hepatol. – 2009. – Vol.51. – P. 237- 267.
6. Germain M. Correlation Between Uremic Pruritus Intensity and Quality of Life: A Report from the ITCH National Registry / M. Germain et al. // American Society of Nephrology. – 2008. – Abstract TH-PO798.
7. Gershwin M.E. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells / M.E. Gershwin, A.A. Ansari, Mackay et al. // Immunol Rev. – 2000. – Vol. 174. – P. 210-225.
8. Grimstad O. Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis / O Grimstad et al. // Exp Dermatol. – 2009. – Vol. 18(1). – P. 35-43.
9. Guyatt G.H GRADE: an emerging consensus on rating quality of evidence and strength of recommendations / G.H. Guyatt et al. // BMJ. – 2008. – Vol.336. – P. 924-926.
10. Heathcote E.J. Management of primary biliary cirrhosis The American Association for the Study of Liver Diseases practice guidelines / E.J. Heathcote //. Hepatology. – 2000. – Vol.31(4). – P. 1005-1013.
11. Jones E.A. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis / E. A. Jones, L.R. Dekker // Gastroenterology.
– 2000. – Vol.118. – P. 431-432.
12. Keith D. et al. Primary biliary cirrhosis The American Association for the Study of Liver Diseases practice guidelines / D. Keith et al. // Hepato logy. – 2009. – Vol. 50 (1). – P. 291-308.
13. Kremer A.E. Pathogenesis and treatment of pruritus in cholestasis / A.E. Kremer, U. Beuers, R. P. Oude-Elferink, T. Pusl // Drugs. – 2008. – Vol. 68(15). – P. 2163-2182.
14. Lammert F. // J Hepatol. – 2000. – Vol. 33. – P. 1012-1021.
15. Maggs J.R. An update on primary sclerosing cholangitis / J.R. Maggs, R.W. Chapman // Curr Opin Gastroenterol. – 2008. – Vol.24. – P. 377-383.